Results 141 to 150 of about 25,778,187 (334)
, 2006 Cathepsin B is a cysteine protease that in tumor tissues is localized in both acidic lysosomes and extracellular spaces. It can catalyze the cleavage of peptide bonds by two mechanisms: endoproteolytic attack with a pH optimum around 7.4, and attack from
BIONDI B +7 more
core +1 more source
Arthritis &Rheumatology, Accepted Article.Objectives To elucidate role of beta‐transducin repeat‐containing protein 2 (β‐TrCP2) in bone homeostasis for its potential as a therapeutic target for osteoporosis. Methods The role of β‐TrCP2 in bone phenotypes was investigated using systemic β‐TrCP1KO and β‐TrCP2KO mice, along with myeloid‐specific conditional β‐TrCP2KO (β‐TrCP2ΔM) mice.
Woo Jung Kim +14 more
wiley +1 more source
Effect of HIV infection on cathepsin B secretion in macrophages.
, 2012 Cell supernatants (n = 4) from HIVADA-infected (solid bars) and uninfected (open bars) macrophage cultures were collected, centrifuged, and tested for cathepsin B, cystatin B and cystatin C expression by antigen capture ELISA.
Carmen L. Cadilla (160681) +8 more
core +1 more source
Safety and pharmacokinetics of inhaled aloxistatin: A first‐in‐human phase 1 dose escalation trial
British Journal of Clinical Pharmacology, EarlyView.Aims Aloxistatin (E64d) is a membrane‐permeable cysteine protease inhibitor prodrug that is converted by esterases to the active metabolite E64c (loxistatin). This first‐in‐human study evaluated the safety, tolerability and pharmacokinetics of single ascending doses of inhaled E64d in healthy volunteers.
Sebastian Fähndrich +24 more
wiley +1 more source
The role of inflammation in the immune evasion of KRas
Frontiers in ImmunologyKRas, NRas and HRas mutations are recognized in over 25% of all tumors, with the predominant mutations occurring at amino acids G12 or G13. While small molecule inhibitors of KRas show therapeutic promise, KRas has largely resisted control by ...
E. Jane Homan, Robert D. Bremel
doaj +1 more source
Modular and Automated Synthesis of Oligonucleotide-Small Molecule Conjugates for Cathepsin B Mediated Traceless Release of Payloads [PDF]
Attachment of small molecules to oligonucleotides is a versatile tool in the development of therapeutic oligonucleotides. However, cleavable linkers in the oligonucleotide field are scarce, particularly with respect to the requirement of traceless ...
Siqi, Li +4 more
core +1 more source
Biotechnology and Bioengineering, EarlyView.ABSTRACT Modern biopharmaceutical manufacturing requires purification platforms capable of processing structurally and functionally diverse products while addressing the challenge of removing persistent and high‐risk host cell proteins (HCPs).
Wenning Chu +23 more
wiley +1 more source
Cathepsin B attenuates the CD4-independent HIV-1 vector infection.
, 2013 (A) Cathepsin B activities of control and cathepsin B-overexpressing 293T cells were measured by the cathepsin B detection reagent. The closed area indicates cells not stained with the cathepsin B detection reagent.
Kensuke Goto (200038) +10 more
core +1 more source
Biotechnology and Bioengineering, EarlyView.ABSTRACT Persistence of HCPs remains a major purification challenge in biopharmaceutical manufacturing with direct consequences for product quality, patient safety, and regulatory compliance. Over the last two decades, deeper insights into the mechanisms driving HCP persistence have clarified why certain proteins evade removal during purification ...
Younghoon Oh +10 more
wiley +1 more source
BMEMat, EarlyView.This review comprehensively summarizes emerging biomaterial‐based strategies and underlying mechanisms for modulating endogenous tendon stem/progenitor cells (TSPCs). It offers the most recent insights into TSPC physiology and potential applications of tissue engineering and regenerative medicine in tendons.
Zeyu Zhu +9 more
wiley +1 more source